© 2004 by Oxford University Press
© 2004 Oxford University Press
CORRESPONDENCE |
RESPONSE: Re: Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus
Affiliations of authors: Gastrointestinal Unit (CH, NN) and Institute for Technology Assessment (CH, GSG), Massachusetts General Hospital, Boston
Correspondence to: Chin Hur, MD, Massachusetts General Hospital, Gastrointestinal Unit & Institute for Technology Assessment, 101 Merrimac St., 10th floor, Boston, MA 02114 (e-mail: chur@partners.org)
| The first 10% of the full text of this article appears below. |
We thank Drs. Jankowski and Moayyedi for their comments and agree that chemoprevention for Barrett's esophagus is an extremely timely issue. Our disease model of Barrett's esophagus found that aspirin chemoprevention could be a cost-effective management tool
Related Correspondence
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2004 96: 885-887.
This article has been cited by other articles:
![]() |
J. A. Abrams Are we making progress in preventing Barrett's-related esophageal cancer? Therapeutic Advances in Gastroenterology, March 1, 2009; 2(2): 73 - 77. [PDF] |
||||
